Takeda Pharmaceutical Co. Launches Phase III Clinical Trials for Lymphoma Treatment

Strategic Insights -

Takeda Pharmaceutical Co. has initiated Phase III clinical trials in the U.S., Europe, and Russia for a lymphoma treatment, marking a significant step in the development of SGN-35. This conjugate drug, developed jointly with Seattle Genetics Inc., aims to combine an anti-cancer agent with an antibody targeting an antigen on Hodgkin's lymphoma cells. By running Phase III trials in parallel with ongoing Phase II trials, Takeda hopes to expedite the approval process and make the drug available to patients who have not responded to existing treatments.

Key Takeaways:

  • Takeda Pharmaceutical Co. has launched Phase III clinical trials for SGN-35, a lymphoma treatment being developed in collaboration with Seattle Genetics Inc.
  • The Phase III trials will be conducted in the U.S., Europe, and Russia, with Takeda having marketing rights for the drug in these regions.
  • SGN-35 is a conjugate drug combining an anti-cancer agent with an antibody targeting an antigen on Hodgkin's lymphoma cells, with the goal of attacking cancer cells while sparing normal cells.
  • Approximately 148,000 people in the U.S. and 8,000-9,000 in Europe suffer from Hodgkin's lymphoma, with a significant number not responding to existing treatments.
  • The drug has been fast-tracked for accelerated approval and conditional authorization in the U.S. and Europe, allowing for submission of marketing approval while data are still being collected.
  • Takeda expects to submit SGN-35 for approval in the first half of 2011, pending positive results from the ongoing Phase II trials.

Statistics:

  • 148,000 people in the U.S. suffer from Hodgkin's lymphoma (source: unknown).
  • 8,000-9,000 people in Europe undergo treatment for Hodgkin's lymphoma, with 8,000-9,000 not responding to existing treatments (source: unknown).
  • 60% of people diagnosed with Hodgkin's lymphoma in the U.S. and Europe do not respond to existing treatments and may benefit from SGN-35 (source: unknown).
  • Takeda Pharmaceutical Co. expects to submit SGN-35 for marketing approval in the first half of 2011 (source: Nikkei April 9, 2011).

Sources:

  • (Tokyo, April 9 Asia Pulse
  • Nikkei April 9, 2011